Hal­loween ad­comm post­poned as FDA seeks more Ipsen da­ta on ul­tra rare dis­or­der drug can­di­date

In a new set­back for Paris-based Ipsen, the FDA is post­pon­ing an ad­comm meet­ing that was set for Oct. 31 to re­view new in­for­ma­tion on the com­pa­ny’s pre­vi­ous­ly spurned po­ten­tial treat­ment of pa­tients with fi­brodys­pla­sia os­si­f­i­cans pro­gres­si­va, an ul­tra-rare ge­net­ic dis­or­der.

The FDA said the post­pone­ment is “to al­low time for the FDA to re­view new in­for­ma­tion,” while Ipsen said “the post­pone­ment re­lates to an FDA re­quest for new in­for­ma­tion on palo­varotene clin­i­cal tri­al da­ta and does not re­late to the safe­ty pro­file of palo­varotene. The com­pa­ny is cur­rent­ly work­ing to ful­fill the re­quest.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER